VivoSim Labs (FRA:4OR) Debt-to-Asset : 0.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4OR VivoSim Labs Inc FRA:4OR
33 GF Score
Price €3.49
GF Value €12.30
! 6 Warning Signs
View Full Analysis

What is VivoSim Labs Debt-to-Asset?

VivoSim Labs FRA:4OR 33 Debt-to-Asset is 0.06 as of Mar. 2026. GuruFocus rates FRA:4OR with a GF Score™ of 33/100 and a GF Value™ of €12.30. The stock has 6 warning signs investors should review.

VivoSim Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0.39 Mil. VivoSim Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0.00 Mil. VivoSim Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was €6.39 Mil. VivoSim Labs's debt to asset for the quarter that ended in Mar. 2026 was 0.06.

VivoSim Labs  (FRA:4OR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

VivoSim Labs Debt-to-Asset Related Terms

VivoSim Labs Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Debt-to-Asset Chart

VivoSim Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.09 0.22 0.06 0.06

VivoSim Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.07 0.07 0.08 0.06

FRA:4OR vs SLXN, CDT, CLDI: Debt-to-Asset Comparison

For the Biotechnology subindustry, VivoSim Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VivoSim Labs Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Debt-to-Asset falls into.


FRA:4OR
33GF Score
VivoSim Labs Inc FRA:4OR
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

VivoSim Labs's Debt-to-Asset for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.387 + 0) / 6.389
=0.06

VivoSim Labs's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.387 + 0) / 6.389
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.06 mean?
VivoSim Labs (FRA:4OR) has a Debt-to-Asset of 0.06 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Debt-to-Asset too high?
VivoSim Labs' current Debt-to-Asset is 0.06. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Debt-to-Asset compare to SLXN and CDT?
VivoSim Labs' Debt-to-Asset of 0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Debt-to-Asset is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Debt-to-Asset of 0.06. The stock's GF Value™ is €12.30, compared to a current price of €3.49 — trading 71.6% below its estimated fair value. The current Debt-to-Asset is 0.06. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Debt-to-Asset is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 71.6% below its estimated GF Value™ of €12.30.

Key valuation signals for FRA:4OR:

  • Debt-to-Asset: 0.06
  • GF Value™: €12.30 vs. price of €3.49 (71.6% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score

Get the complete analysis for FRA:4OR

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€12.30
GF Value